Table 6.
Standardized Adjusted Platelet Activation Measures by Metabolic Syndrome Presence
| Platelet activation measure | Metabolic syndrome present | Metabolic syndrome absent | P value (model 1) n = 2036 | P value (model 2) n = 1958 | P value (model 3) n = 1821 |
|---|---|---|---|---|---|
| Collagen (Ω) | 6.2 ± 0.3 | 6.3 ± 0.1 | 0.764 | 0.322 | 0.594 |
| ADP (Ω) | 12.6 ± 0.2 | 12.2 ± 0.1 | 0.059 | 0.060 | 0.123 |
| Arachidonic acida | 1.53 (1.02–2.30) | 1.0 (REF) | 0.038 | 0.090 | 0.294 |
| TxM (ng/mmol creatinine)b | 34.8 (32.5–37.3) | 31.4 (29.9–33.0) | 0.009 | 0.002 | 0.004 |
Whole blood aggregation measures: Aggregation responses in electrical impedence units in response to the agonists Col—1 μg/mL collagen; ADP, 10 μM ADP; AA, 0.5 mM arachidonic acid. Fibrinogen and hs-CRP were log-transformed prior to inclusion as covariates.
TxM is urinary excretion of thromboxane metabolite 11-dehydrothromboxane B2, a measure of in vivo platelet activation. All platelet measures are presented standardized for the average of the study sample 44 years of age, 58% women, 123 mg/dL of LDL, 25% smokers, 40% black, 0.5% other race (model 1), further adjustment for fibrinogen (model 2), and hs-CRP (model 3).
Presented as the odds of nonzero aggregation (95% CI).
Geometric mean and its 95% confidence interval (model 1, n = 1900; model 2, n = 1827; model 3, n = 1687).
Abbreviations: ADP, adenosine diphosphate; TxM, 11-dehydrothromboxane B2; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; CI, confidence interval.